- Home
- SEER vs PLRX Comparison
SEER vs PLRX Comparison
Compare SEER & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SEER | PLRX |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.0M | 93.3M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SEER | PLRX |
|---|---|---|
| Price | $1.90 | $1.24 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $3.79 |
| AVG Volume (30 Days) | 154.7K | ★ 1.2M |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $16,376,999.00 | N/A |
| Revenue This Year | $25.97 | N/A |
| Revenue Next Year | $24.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 12.11 | N/A |
| 52 Week Low | $1.62 | $1.10 |
| 52 Week High | $2.59 | $15.27 |
Technical Indicators
Market Signals| Indicator | SEER | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 35.38 | 32.46 |
| Support Level | $1.91 | $1.48 |
| Resistance Level | $2.02 | $1.63 |
| Average True Range (ATR) | 0.08 | 0.12 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 31.83 | 25.20 |
Price Performance
Historical ComparisonAbout SEER Seer Inc.
Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.